News

Biosceptre and the University of Queensland’s AIBN research institute have teamed up to develop a production method for monoclonal antibodies designed to trigger cancer cell death.

The Australian Synchrotron will use a new tracking technology developed by Bluechiip (ASX:BCT) to keep track of samples in extreme temperatures.

Gene patents have hit the headlines once again with a Labor backbencher introducing a private member’s bill to ban patents on genetic material.

Bioniche (ASX:BNC) revealed its burn rate increased in the March quarter as it stepped up efforts to improve its bottom line through increased animal health sales.

US sales of generic fondaparinux, the anticoagulant produced by Alchemia (ASX:ACL), are expected to have grown 120% year-on-year.

Professor Trevor Lithgow is tinkering with the cogs of bacteria to understand how they, and their mitochondrial cousins, tick.

Ventus Medical plans to use the proceeds of its upcoming ASX IPO to fund efforts to build a market for its sleep disorder breathing products.

Retail chain David Jones has agreed to stock the Elixia range of skincare products from Melbourne-based Phosphagenics (ASX:POH).

Cardiac catheter company CathRx (ASX:CXD) will likely seek shareholder approval to go private after it raises funds to pursue a potential sale of the company.

BioDiem (ASX:BDM) and France's VIVALIS are exploring the feasibility of using BioDiem's LAIV flu virus to create a viral vector for non-influenza vaccines.

Despite a budget riddled with cuts, funding for science has increased and the recently-passed R&D Tax Incentive has remained intact.

BioDiem (ASX:BDM) has received license fees totalling around 10% of its market cap from its LAIV flu vaccine technology.

Hydrix, an engineering consultancy company operating in the medical device and other sectors, has won an award from the Victorian Manufacturing Hall of Fame.

TGA names national manager; Hatchtech appoints new CEO; Starpharma’s new director; Immuron CEO; University of Queensland vice chancellor and president.

Immuron (ASX:IMC) has signed a deal with dairy processing company Synlait covering the production of colostrum needed for its Travelan drug.

Contract medical company IQnovate (ASX:IQN) has signed an MoU with Sydney's Nanosonics to help commercialise an ultrasound disinfection system.

Clinical trials could be made more transparent, allowing greater sharing of knowledge and improved clinical outcomes, if they were modelled after the open source software movement, say researchers.

Bioniche (ASX:BNC) is commercialising two products designed to treat cancer in man's best friend, including an immunotherapy for mammary cancer.

AtCor Medical (ASX:ACG) has launched SphygmoCor XCEL, the newest iteration of its non-invasive central aortic blood pressure monitoring device.

Shares in Osprey Medical (ASX:OSP), a US medical device company commercialising a product which uses Australian IP, began trading on the ASX on Wednesday.